|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-55.43/-2.29
|
企业价值
492.18M
|
资产负债 |
每股账面净值
0.03
|
现金流量 |
现金流量率
--
|
损益表 |
收益
26.00M
|
每股收益
0.32
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/12/23 22:17 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material. |